Targeting Underlying Disease Biology
65 / 199 active trials monitored as priority pipeline programs
74
88
Phase I Phase II
37
Phase III
levodopa , and Abbvie ’ s ABBV951 delivers carbidopa-levodopa solution continuously under the skin via an infusion pump ( a less invasive version of the company ’ s previously approved Duopa , which requires surgery to implant a tube into the small intestine ). Supernus ’ s SPN830 , which uses an infusion pump to deliver apomorphine , is expected to submit an application for FDA approval before the end of the year . The FDA responded to prior submissions of ABBV951 and SPN830 by requesting more information , particularly about the pump device that each therapy uses .
+ Two more medications to increase dopamine levels are in Phase III : Cerevel ’ s tavapadon , which targets two receptors in the dopamine pathway , and NeuroDerm ’ s ND0612 , which , similar to AbbVie ’ s ABBV951 , delivers a combination of levodopa and carbidopa via subcutaneous pump .
19